GSK Reports the NMPA Approval of Exdensur (Depemokimab) for Severe Asthma

Why It Matters

The clearance gives GSK a foothold in China’s fast‑growing biologics market and offers clinicians a highly effective option for a hard‑to‑treat asthma phenotype, potentially reshaping treatment standards.

Key Takeaways

• Exdensur approved in China for severe eosinophilic asthma
• Reduces exacerbations 58% in SWIFT‑1, 48% in SWIFT‑2
• Hospitalizations drop 72% versus placebo plus standard care
• Under review for chronic rhinosinusitis with nasal polyps

Pulse Analysis

China’s asthma burden is substantial, with an estimated 30 million adults affected and a growing prevalence of eosinophilic phenotypes that respond poorly to conventional inhaled therapies. GSK’s entry with Exdensur marks the first biologic targeting this subgroup to secure NMPA approval, signaling confidence in the drug’s safety profile and manufacturing standards. The move aligns with Beijing’s push to accelerate access to advanced biologics, offering patients a novel mechanism of action that complements existing inhaled corticosteroids and long‑acting bronchodilators.

The SWIFT‑1 and SWIFT‑2 Phase III trials underpin the regulatory decision, delivering robust efficacy signals across diverse Asian cohorts. In SWIFT‑1, Exdensur cut annualized exacerbation rates by 58%, while SWIFT‑2 showed a 48% reduction, both over a 52‑week period. Notably, a subgroup analysis of 58 Chinese participants mirrored the global outcomes, reinforcing the drug’s relevance to the local population. Hospitalization rates fell by 72% versus placebo plus standard of care, and emergency‑room visits declined sharply, translating into tangible health‑system savings and improved quality of life for patients.

Looking ahead, GSK’s strategy extends beyond asthma. The ongoing NMPA review for Exdensur as an adjunct to intranasal corticosteroids in chronic rhinosinusitis with nasal polyps could broaden the product’s addressable market and deepen its therapeutic footprint. Success would position GSK as a leader in type‑2 inflammation treatments within China, potentially accelerating future biologic launches and partnerships in the region’s lucrative pharmaceutical landscape.